Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Xiaofeng Zeng, Hongtao Jin et al.|Annals of the Rheumatic Diseases|2025Cited by 17